Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM22 in NSCLC patients receiving cisplatin + etoposide chemotherapy
2009-016000-22Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Jan 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing XM22 arm with Placebo arm (2 arms). Primary endpoint: Incidence of febrile neutropenia in first chemotherapy cycle. Started Jan 2010; status: completed.
02
Drugs
lipegfilgrastim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-016000-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016000-22.